Trial reportEmerging infectious diseases2019
Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease.
Trial report in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06590207 (Administering Convalescent Plasma Rich With Neutralizing Abs. to Hospitalized Adults With WNV - a Double-blind Randomized Controlled Study), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Administering Convalescent Plasma Rich With Neutralizing Abs. to Hospitalized Adults With WNV - a Double-blind Randomized Controlled Study
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Efficacy and safety of intravenous immunoglobulins for the treatment of viral encephalitis: a systematic literature review.Journal of neurology · 2022Pooled it
- West Nile virus: epidemiology, prevention, clinical features, diagnosis, treatment, and open research questions.Annals of medicine · 2026Review
- West Nile Virus in People with HIV: Immune Vulnerability, Neuroinvasive Disease, and Diagnostic Challenges.Tropical medicine and infectious disease · 2026Review
- Article
- West Nile Neuroinvasive Disease: Current Management, Emerging Therapies and Future Clinical Trial Priorities.Reviews in medical virology · 2026Review
- Human antibodies against West Nile and related orthoflaviviruses.bioRxiv : the preprint server for biology · 2026Article
- Case Report: First case of West Nile virus meningoencephalitis in Southwest Michigan in a patient on ixekizumab and prednisone.Frontiers in medicine · 2026Article
- Article
- West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies.Neurology. Clinical practice · 2025Article
- Abdominal Clues From a Neurotropic Virus: An Atypical West Nile Case Caught During a Fever of Unknown Origin Workup.Cureus · 2025Article
- Variations in West Nile viral infections across North and Central Texas.Proceedings (Baylor University. Medical Center) · 2025Article
- Article
- Clinical and Diagnostic Features of West Nile Virus Neuroinvasive Disease in New York City.Pathogens (Basel, Switzerland) · 2024Article
- Neuroinvasive West Nile Virus Infection in Immunosuppressed and Immunocompetent Adults.JAMA network open · 2024Article
- Clinical efficacy of immunoglobulin on the treatment of severe fever with thrombocytopenia syndrome: a retrospective cohort study.EBioMedicine · 2023Article
- Arthropod-borne encephalitis: an overview for the clinician and emerging considerations.Postgraduate medical journal · 2023Review
- The WEST Study: A Retrospective and Multicentric Study on the Impact of Steroid Therapy in West Nile Encephalitis.Open forum infectious diseases · 2023Article
- Arthropod-Borne Flaviviruses in Pregnancy.Microorganisms · 2023Review
- Neurology of Acute Viral Infections.The Neurohospitalist · 2022Review
- Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.Human vaccines & immunotherapeutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
West Nile Virus (WNV) can result in clinically severe neurologic disease. There is no treatment for WNV infection, but administration of anti-WNV polyclonal human antibody has demonstrated efficacy in animal models. We compared Omr-IgG-am, an immunoglobulin product with high titers of anti-WNV antibody, with intravenous immunoglobulin (IVIG) and normal saline to assess safety and efficacy in patients with WNV neuroinvasive disease as part of a phase I/II, randomized, double-blind, multicenter study in North America. During 2003-2006, a total of 62 hospitalized patients were randomized to receive Omr-IgG-am, standard IVIG, or normal saline (3:1:1). The primary endpoint was medication safety. Secondary endpoints were morbidity and mortality, measured using 4 standardized assessments of cognitive and functional status. The death rate in the study population was 12.9%. No significant differences were found between groups receiving Omr-IgG-am compared with IVIG or saline for either the safety or efficacy endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.